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Abstract
We studied 786 undiagnosed patients with LGMD or nonspecific myopathic features to investigate the role of ANO5 mutations in limb-girdle
muscular dystrophies (LGMDs) and in nonspecific myopathies using the next generation sequencing (NGS) approach. In 160 LGMD patients, we
first sequenced hotspot exons 5 and 20 and then sequenced the remaining part of the coding region. Another 626 patients, recruited using broader
inclusion criteria, were directly analyzed by targeted NGS. By combining NGS and Sanger sequencing, we identified 33/786 (4%) patients carrying
putative pathogenic changes in both alleles and 23 ANO5 heterozygotes (3%). The phenotypic spectrum is broader than expected, from
hyperCKemia to myopathies, with lack of genotype/phenotype correlations. In particular, this is currently the largest screening of the ANO5 gene.
The large number of heterozygotes for damaging mutations suggests that anoctaminopathies should be frequent and often nonpenetrant. We
propose the multiple genetic testing by targeted NGS as a first step to analyze patients with nonspecific myopathic presentations. This represents
a straightforward approach to overcome the difficulties of clinical heterogeneity of ANO5 patients, and to test, at the same time, many other genes
involved in neuromuscular disorders.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/
by/4.0/).
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1. Introduction
The diagnosis of autosomal recessive limb-girdle muscular
dystrophies (LGMDs) is complex for the presence of a number
of different conditions with similar clinical presentation [1].
The genetic studies have demonstrated the involvement of at
least 23 different genes for the LGMD2 forms [2] and others
that are involved in metabolic, congenital or other myopathies
that can also present with a clinical LGMD-like phenotype [3].
For the correct diagnosis of specific forms four elements may
be of pivotal importance: 1) the clinical picture; 2) the muscle
biopsy; 3) the imaging; 4) the DNA results, with the last
approach that is changed dramatically in the course of the
present study. We have studied one of the most interesting
forms of LGMD that is caused by recessive mutations in a gene
coding for a calcium-activated chloride channel, known as
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anoctamin 5 (ANO5) [4]. The ANO5 gene at 11p14.3 spans
90,192 bp and contains 22 exons, the coding sequence is 2.7 kb
for 913 amino acids. This form, according to the order of
mapping, has been defined as LGMD2L. Genetic studies in
some countries have shown that LGMD2L may be a very
common form of LGMD [5]. In place of the proximal
limb-girdle presentation, some patients show Miyoshi-like
muscular dystrophy type 3 (MMD3) [6]. Dominant variations
in the same gene have been associated to gnathodiaphyseal
dysplasia (GDD) [7].
The LGMD2L phenotype was described for the first time in
2007 in 14 patients of French Canadian origin, showing atrophy
and weakness of the quadriceps and biceps brachii muscles [8].
In 2010, ANO5 was identified as the causative gene [4]. More
recently, it has been indicated as the third most common form of
LGMD in the North of Europe and the c.191dupA mutation has
been shown to be the most prevalent because of a founder effect
[5,9].
Distinctive features of LGMD2L versus other LGMD forms
are: 1) the sex imbalance, with females that are less frequently
or severely affected than males [10]; 2) asymmetry of muscle
involvement that is rare among the LGMD and frequent in FSH
[4]; 3) the pain following exercise that is typical of metabolic or
inflammatory conditions [11].
All the previous studies have evidenced the extreme
heterogeneity of the observed phenotypes, comprising the
asymmetric atrophy and weakness affecting primarily the
quadriceps, hamstrings and biceps, an adulthood onset and a
slow progression [4,5,10,12,13]. The weakness of both distal
and proximal lower limbs, exercise intolerance, a so called
“pseudometabolic” phenotype and also amyloid deposits in the
muscles [11,14] are all features present in patients affected by
anoctaminopathy or dysferlinopathy [15].
In this paper, we describe the results of a genetic screening in
a subset of patients with a broad clinical phenotype of
LGMD or generic myopathy. In total, we have fully sequenced
the ANO5 gene in 786 patients using Sanger and/or Next
Generation Sequencing (NGS): in this cohort, we have found
33 cases belonging to 28 families. Our data confirm the genetic
heterogeneity of the ANO5 gene and highlight the weak
genotype–phenotype correlation.
2. Methods
2.1. Sample collection
From a large collection of families with a clinical diagnosis
of LGMD or with molecularly uncharacterized myopathy, we
recruited 786 patients. In particular, 712/786 (90.6%) patients
were from Italian families. Additional patients (n = 74) were
from Belgium (39), France (8), Finland (4), Brazil (3), Turkey
(3), Romania (3), Morocco (3), Germany (2), Russia (2),
Greece (1), Israel (1), Uganda (1), Spain (1), Libya (1), Cyprus
(1) and The Netherlands (1),
In all the cases, genomic DNA has been tested and, when
available, a further analysis on mRNA from blood or from
muscle has been performed.
2.2. Clinical and diagnostic criteria
Based on literature evidence, as a first step, we screened 160
patients for mutations in exon 5 and in exon 20. Because of the
low mutation rate detected in these exons, we extended the
analysis to all the other exons.
All the patients recruited for the first step have an LGMD or
an LGMD-like phenotype, including a raised serum creatine
kinase (CK), progressive muscle weakness affecting primarily
the shoulder girdle and pelvic muscles and a muscle biopsy
with dystrophic features. All of them show an autosomal
recessive inheritance or are sporadic cases. Moreover, most
(about 85%) of the 160 samples analyzed by PCR and Sanger
sequencing had resulted negative for mutations in DYSF and
CAPN3 genes.
Another 626 samples were recruited for NGS, including all
the ANO5 exons and the 10 flanking nucleotides.
The inclusion criteria for the NGS screening were less
stringent. Samples of still living patients, affected by an
uncharacterized muscular dystrophy (65%) or myopathy (35%),
were included. These patients had a wide spectrum of clinical
phenotypes, ranging from an isolated hyperCKemia to mild or
severe conditions with a variable age of onset and progression.
A large portion of these patients (30%) had not been screened
previously and less than 20% had been analyzed for mutations
in LGMD recessive genes (in particular CAPN3, DYSF or
sarcoglycan genes).
Moreover, DNA samples from 52 unaffected people were
sequenced as a control group.
Written informed consent for DNA analysis was obtained
from all the recruited patients or their caregivers when primary
diagnostic procedures were performed, with explicit consent for
future use for research purposes, according to the Declaration
of Helsinki. Approval for the study was obtained by the
Seconda Università di Napoli Ethics Committee.
2.3. Molecular analysis
Genomic DNA was extracted from peripheral blood by
phenol/chloroform.All the ANO5 exons have been amplified by
PCR using M13-tailed primers. M13 primers have been used to
perform Sanger sequencing using an ABI PRISM 3130 XL
automatic DNA Sequencer Genetic Analyzer (Applied
Biosystems, Foster City, CA, USA). We used a TRIzol
reagent (Invitrogen, Carlsbad, CA, USA) according to the
manufacturer’s instructions to extract RNA from the muscle
biopsies and the PAXgene Blood RNA Kit (Qiagen, Hilden,
Germany) to extract RNA from the blood.
The retrotranscription reaction was performed using 2 mg of
total mRNA, according to the procedure described in the
SuperScript III kit (Invitrogen).
We amplified the ANO5 cDNA in seven overlapping
fragments. Supplementary Table S1 lists primers and PCR
conditions.
For NGS screening, samples were enriched using
HaloPlex Target Enrichment System (Protocol version D,
August 2012, Agilent Technologies, Santa Clara, CA, USA)
[16].
534 M. Savarese et al. /Neuromuscular Disorders 25 (2015) 533–541
For each of the novel mutations identified, amino acid
change, presence in dbSNP v137 [17], frequency in NHLBI
Exome Variant Server (http://evs.gs.washington.edu/EVS) and
1000 genomes large scale projects (http://www.1000genomes
.org) [18], conservation and causative effects, using different
prediction algorithms [19–21], were evaluated.
To assess intronic and exonic mutations leading to splicing
defects, a free bioinformatic tool (http://www.fruitfly.org/seq
_tools/splice.html) [22] was consulted.
3. Results
To study 160 patients with undiagnosed LGMD, we first
sequenced the hotspot regions at exons 5 and 20 of the ANO5
gene, but the screening was diagnostic in two families only (I
and XVI, homozygotes for c.191dupA and c.2272 C > T,
respectively). Ten additional patients were heterozygous for a
single ANO5 mutation. We next extended the analysis to all the
other exons by PCR and Sanger sequencing. By this exon-by-
exon scanning, we were able to detect another fourteen
mutations, concluding the genetic diagnosis in other 15 patients
(Table 1).
To profit from the extraordinary throughput of next
generation sequencing [23], we included the ANO5 gene in a
large and accurate screening of genes causing neuromuscular
disorders [16]. In particular, the ANO5 exons and the ten
flanking bases were >90% covered at no less than 100×
(Supplementary Fig. S1) after a Haloplex-based enrichment.
We studied further 626 patients with broader phenotypic
presentation, ranging from classic LGMD phenotype to
congenital myopathies, nonspecific myopathic features or
hyperCKemia. In this way, we identified other 15 ANO5
patients. All the variants identified by NGS were then
confirmed by the dideoxy method. Interestingly, we detected
different ANO5 variants in both alleles in patients XVIII and
XXIV. These were classified as affected by a congenital
myopathy with a hypothesized dominant transmission.
However, they did not show mutations in the other genes
causing congenital myopathies. Considering their specific
phenotype and the unavailability of other relatives’ samples to
study the status and the segregation of their mutations, we were
not able to correctly interpret them.
We also identified 23 patients with a single mutated allele,
including one (XXXVIII) with two mutations in cis on the same
chromosome.
To avoid the risk to miss mutations, the DNA samples from
heterozygous patients were also resequenced exon-by-exon and
no additional variations were detected. Array-CGH (Motorchip
[24]) testing was also negative.
Finally, three normal control samples also showed
heterozygous variants in ANO5, including a novel missense
substitution (ctrl1).
By combining NGS and Sanger sequencing, we identified
33/786 individuals, from 28 different families, homozygous or
compound heterozygous for mutations in the ANO5 gene.
Forty-three mutations were detected in 16/22 exons. Twelve of
them had already been detected and described in literature; on
the contrary, thirty-one had never been described previously
(Table 1).
3.1. Novel mutations
3.1.1. Missense and nonsense mutations
Twenty-four novel missense and nonsense mutations were
detected. In particular, four of them (c.1207 C > T, c.1213
C > T, c.1261 C > T and c.1639 C > T) introduced a premature
stop codon. All the other variants determined an amino acidic
change and their clinical significance was evaluated by different
bioinformatic tools.
The mutations identified in homozygosity (c.161 T > C in II
and c.2498 T > A in VII) or in compound heterozygosity
(c.2489 C > T in XV, c.2342 in XLV and c.2411C > G in XLII)
were all predicted to be causative by at least two out of three
tools.
3.1.2. Point mutations modifying a splicing site consensus
Four point mutations (c.294 G > A; c.649-2 A > G;
c.1119 + 1 G > A and c.2235 + 1 G > A) were expected to
modify a splicing site, as suggested by bioinformatic tools. We
analyzed ANO5 mRNA in the leukocytes (for patient XXII) or
in the muscle (V), to confirm the splicing effect. As detected on
control samples, the leukocyte ANO5 isoform lacks exon 4, but
maintains the reading frame and determines a predicted protein
14 amino acids smaller (Fig. 1).
In patient XXII, the mutation produces a shortened mRNA
without exons 4 and 5 (Fig. 2A, B). The extra-skipping of exon
5 causes an in-frame deletion of 114 nucleotides encoding 38
amino acids. However, both DNA and RNA analyses did not
allow us to detect a second mutation in this patient that remains
formally undiagnosed.
The muscular mRNA of patient V revealed the activation of
a cryptic splice site 20 nucleotides upstream the natural 3′ end
of exon 11 (Fig. 2C–D). The frame-shift results in a premature
stop codon after five amino acids. For splice site mutations in
patients XIX and XX, we did not study muscle mRNA, but
there is little doubt about their deleterious effect.
3.1.3. Small deletions and insertions
We found two small deletions in the same patient (VI). In
particular, in exon 6 we detected a c. 304–308 delAAAGA,
causing a frame-shift with the substitution of a Lysine with a
Valine 102 and a premature stop codon after a single amino
acidic residue.
In exon 19, we found a 3-nucleotide deletion c. 2102–2105
delATA, causing the loss of an Asparagine 701. This residue,
evolutionarily conserved, is the first amino acid of the putative
sixth cytoplasmatic loop and its loss is predicted to be
damaging.
An insertion of a single nucleotide was found in one allele of
patient XLVII and it determined an immediate premature stop
codon.
3.2. Phenotypic spectrum of ANO5 patients
As already reported [10], also in our cohort of patients, the
number of affected males (21 = 64%) was higher than that of
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Table 1
List of patients and controls with ANO5 variants.
Sample ID Status Mutations
I,1s hom c.191 dupA (exon 5) p.Asn64LysfsX156
I,2f hom c.191 dupA (exon 5) p.Asn64LysfsX156
IIs hom c.161T > C (exon 4) p.Phe54Ser
IIIs hom c.172C > T (exon 4) p.Arg58Trp31
IV,1s c.het c.1733T > C (exon 16) p.Phe578Ser8 + c.2272C > T (exon 20) p.Arg758Cys6
IV,2f c.het c.1733T > C (exon 16) p.Phe578Ser8 + c.2272C > T (exon 20) p.Arg758Cys6
Vs c.het c.1119 + 1 G > A (exon 11) p.Ser367IlefsX5 + c.2272C > T (exon 20) p.Arg758Cys6
VIs c.het c.304–308 delAAAGA (exon 6) p.Lys102ValfsX1 + c.2102–2105 delATA (exon 19) p.ΔAsn701
VIIs hom c.2498T > A (exon 21) p. Met833Lys
VIIIs hom c.1639C > T (exon 16) p.Arg547X
IX,1s c.het c.191 dupA (exon 5) p.Asn64LysfsX156 + c.1733T > C (exon 16) p. Phe578Ser8
IX,2f c.het c.191 dupA (exon 5) p.Asn64LysfsX156 + c.1733T > C (exon 16) p. Phe578Ser8
X,1s c.het c.191 dupA (exon 5) p.Asn64LysfsX156 + c.2516T > G (exon 21) p.Met839Arg16
X,2f c.het c.191 dupA (exon 5) p.Asn64LysfsX156 + c.2516T > G (exon 21) p.Met839Arg16
XIs c.het c.191 dupA (exon 5) p.Asn64LysfsX156 + c.1261C > T (exon 13) p.Gln421X
XIIngs hom c.692G > T (exon 8) p.Gly231Val6
XIIIngs hom c.191 dupA (exon 5) p.Asn64LysfsX156
XIV,1ngs hom c.1627dupA (exon 15) p.Met543Asn fsX1017
XIV,2f hom c.1627dupA (exon 15) p.Met543Asn fsX1017
XVs c.het c.191 dupA (exon 5) p.Asn64LysfsX156 + c.2489C > T (exon 21) p.Ala830Val
XVIs hom c.2272C > T (exon 20) p.Arg758Cys6
XVIIs c.het c.1520 delT (exon 15) p.Phe507SerfsX617 + c.1898-4A > G (exon 18) spl.?17
XVIIIngs het/c.het c.616A > G (exon 7) p.Thr206Ala + c.1211G > T (exon 13) p.Arg404Leu
XIXngs hom c.2235 + 1G > A (exon19) spl.?
XXngs hom c.649-2A > G (exon8) spl.?
XXIngs c.het c.191 dupA (exon 5) p.Asn64LysfsX156 + c.1213C > T (exon 13) p.Gln405X
XXIIs het c.294G > A(exon 5) p.Ala98Ala spl.?
XXIIIs het c.1640G > A (exon 16) p.Arg547Gln
XXIVngs het/c.het c.191 dupA (exon 5) p.Asn64LysfsX156 + c.2387C > T (exon20) p.Ser796Leu32
XXVngs het c.2698A > C (exon 22) p.Met900Leu
XXVIngs het c.279C > G (exon 5) p.Asp93Glu
XXVIIngs het c.797 C > T (exon 9) p.Pro266Leu
XXVIIIngs het c.428A > G (exon 7) p.Tyr143Cys
XXIXngs het c.777G > T (exon 9) p.Lys259Asn
XXXngs het c.2141C > G (exon 19) p.Thr714Ser17
XXXIngs het c.294G > A(exon 5) p.Ala98Ala spl.?
XXXIIngs het c.2141C > G (exon 19) p.Thr714Ser17
XXXIIIngs het c.604G > A (exon 7) p.Glu202Lys
XXXIVngs het c.800C > G (exon 9) p.Thr267Ser
XXXVngs het c.692G > T (exon 8) p.Gly231Val6
XXXVIngs het c.155A > G (exon4) p.Asn52Ser32
XXXVIIngs het c.1664G > T (exon 16) p.Ser555Ile
XXXVIIIngs het c.259G > A p.Val87Ile (exon 5) + c.692G > T (exon 8) p.Gly231Val6 [in cis]
XXXIXngs het c.2387C > T (exon20) p.Ser796Leu32
XLngs het c.191 dupA (exon 5) p.Asn64LysfsX156
XLIngs het c.794A > G (exon9) p.Asn265Ser
XLIIngs c.het c.1207C > T (exon 13) p.Gln403X + c.2411C > G (exon 20) p.Cys804Ser
XLIIIngs c.het c.191 dupA (exon 5) p.Asn64LysfsX156 + c.1520 delT (exon 15) p.Phe507SerfsX617
XLIVngs hom c.191 dupA (exon 5) p.Asn64LysfsX156
XLVngs c.het c.692G > T (exon 8) p.Gly231Val6 + c.2342T > C (exon 20) p.Leu781Pro
XLVIngs c.het c.1213C > T (exon 13) p.Gln405X + c.2387C > T (exon20) p.Ser796Leu32
XLVIIngs c.het c.729_730insT (exon 8) p.Asn244X + c.2387C > T (exon20) p.Ser796Leu32
XLVIIIngs het c.155A > G (exon4) p.Asn52Ser32
XLIXngs het c.1516A > G (exon15) p.Ser506Gly
Lngs het c.2141C > G (exon 19) p.Thr714Ser17
LIngs het c.2516T > G (exon 21) p.Met839Arg16
ctrl1ngs het c.1854G > C (exon 17) p.Met618Ile
ctrl2ngs het c.2387C > T (exon20) p.Ser796Leu32
ctrl3ngs het c.2387C > T (exon20) p.Ser796Leu32
s = Sanger sequencing; f = familial; ngs = NGS analysis; hom = homozygous; het = heterozygous; c.het = compound heterozygous.
Novel mutations are in bold.
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females (12 = 36%). The age of onset varied significantly
(mean = 26.81; min = 13; max = 44). Interestingly, four ANO5
patients (IV,1; IV,2; X,2; XIV,2) are still asymptomatic even if
they showed increased CK serum levels. The average CK values
were 3200 IU/l ranging from 500 IU/l to 9800 IU/l.
The clinical signs of patients with LGMD2L presentation,
such as the early asymmetric quadriceps weakness, the high CK
and the slow progression, and the histological features,
including mild myopathic changes, were in agreement with
literature data (Table 2) [13,25–27]. All the patients are still
Fig. 1. Alternative splicing of exon 4. ANO5 mRNA in muscle shows the full-length isoform containing the exon 4 (A). Blood isoform is differentially spliced, the
exon 4 is removed and the exon 3 is directly joined with the exon 5 (B).
Fig. 2. Intronic mutations affecting the splicing in patients XIX and V. In patient XIX, the G > A mutation in the last exonic nucleotide (A) causes the loss of the
canonical splicing site (B). In blood cDNA, the sequence shows the normal splicing, which connects exon 3 and exon 5, and the abnormal splicing with the complete
loss of exon 4. In patient V, the G > A mutation in the first intronic nucleotide (C) causes the activation of a cryptic splicing site twenty nucleotides upstream (D),
as evidenced on muscular cDNA. The loss of the last twenty nucleotides of exon 11 produces a frame-shift and a premature stop codon five amino acids later.
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Table 2
Clinical features.
Patient
ID
Sex Current
age
Age of
onset
CK, IU/l,
range
ECG and
ultrasound
Spirometry Clinical phenotype Biopsy Loss of walking Genotype
I,1 M 63 37 2800–9800 Normal NA Hyper-Ck-emia, lower quadriceps pain and
later mild weakness
Muscular dystrophy
with regenerating and
necrotic fibers, variation
in fibers size (small and
hypertrophic)
No c.191 dupA; p.Asn64LysfsX15 + c.191
dupA; p.Asn64LysfsX15
I,2 F 35 32 2000–3000 Normal NA Hyper-CK-emia, followed by lower
quadriceps pain doing stairs
NA No
II M 51 36 3000–7000 NA NA Weakness of ankle plantar flexors,
hamstrings and quadriceps, hypotrophy
Mild dystrophic changes No c.161T > C; p.Phe54Ser + c.161T > C;
p.Phe54Ser
III M 31 16 1000–2000 Normal Normal Hypertrophy of calves, cramps and
fatigability
Sparse rounded
hypotrophic fibers and
some splitting fibers
No c.172C > T; p.Arg58Trp + c.172C > T;
p.Arg58Trp
IV,1 M 31 19 >5000 Normal Normal Hyper-Ck-emia, still asymptomatic NA No c.1733T > C;
p.Phe578Ser + c.2272C > T;
p.Arg758Cys
IV,2 F 20 15 1000–2000 Normal Normal Hyper-Ck-emia, still asymptomatic NA No
V F 39 24 3000–4000 PQ short Normal Distal weakness arm, hyper-CK-emia,
myalgia, painful contractures
Mitochondrial myopathy No c.1119 + 1 G > A;
p.Ser367IlefsX5 + c.2272C > T;
p.Arg758Cys
VI F 44 39 3000–4000 Normal Normal Absence of weakness, mild calf hypotrophy Central nuclei and
increased fiber size
No c.304–308 delAAAGA;
p.Lys102ValfsX1 + c.2102–2105
delATA; p.ΔAsn701
VII M 46 17 3500–8000 Normal Normal Weakness of ankle dorsal and plantar
flexors, hamstrings and adductors
Mild dystrophic changes No c.2498T > A; p.
Met833Lys + c.2498T > A; p.
Met833Lys
VIII M 75 37 500–2500 Normal Normal Symmetric proximo-distal lower limb
weakness, quadriceps and calf atrophy,
abdominal and neck flexors muscles
weakness and dysphonia
NA No (walk with
canes)
c.1639C > T;
p.Arg547X + c.1639C > T; p.Arg547X
XVIII F 57 30 1000 NA NA Hyper-Ck-emia, lower quadriceps pain,
possible congenital myopathy
Dystrophic changes No (difficulties in
deambulation)
c.616A > G;
p.Thr206Ala + c.1211G > T;
p.Arg404Leu
IX,1 M 33 17 1600–8700 Normal NA Mild shoulder girdle weakness and atrophy,
moderate scapular winging, mild pectoral
muscle atrophy, mild facial weakness,
global mildly decreased muscle mass limbs
and trunk
Mild dystrophy, splitting
fibers, slight increase in
internal nuclei, slight
type I fiber
predominance
No c.191 dupA;
p.Asn64LysfsX15 + c.1733T > C; p.
Phe578Ser
IX,2 M 29 20 1000–2300 Normal NA Mild shoulder girdle weakness w/o atrophy
or scapular winging, mild pectoral muscle
atrophy, mild dorsal and volar forearm
muscle atrophy and mild facial weakness
Moderate increase in
fibers with central
nuclei
No
X,1 M 47 28 >3000 Normal Normal Hyper-Ck-emia, cramps, myalgia Mild fiber size
variability
No c.191 dupA;
p.Asn64LysfsX15 + c.2516T > G;
p.Met839ArgX,2 F 50 NA 500–1500 NA NA Hyper-Ck-emia, still asymptomatic NA No
XI M 44 30 2200–3000 Normal Normal Progressive atrophy and weakness of biceps
brachii muscles, hamstrings and hip
adductors
Myopathic changes and
necrotic fibers
No (difficulties in
climbing stairs)
c.191 dupA;
p.Asn64LysfsX15 + c.1261C > T;
p.Gln421X
XII M 71 32 2700–7800 Normal FVC = 60%, lying:
50%, use of BIPap
Symmetric proximal UL and proximo-distal
LL weakness with quadriceps and calf
atrophy , abdominal and neck flexors
muscles weakness and swallowing problems
Mild dystrophic changes No (but sporadic
use of wheelchair)
c.692G > T;
p.Gly231Val + c.692G > T;
p.Gly231Val
XIII M 38 32 1500–3000 Normal Normal Diffuse myalgia, fatigability, absence of
weakness and mild unilateral calf
hypotrophy.
Minimal changes with
increased fiber
variability
No c.191 dupA; p.Asn64LysfsX15 + c.191
dupA; p.Asn64LysfsX15
XIV,1 M 45 40 >1000 Normal NA Myalgia and cramps Mild dystrophic changes No c.1627dupA; p.Met543Asn
fsX10 + c.1627dupA; p.Met543Asn
fsX10
XIV,2 M 38 NA >1000 Normal NA Hyper-Ck-emia, still asymptomatic NA No
XIX M 54 44 2000–3000 NA NA easy fatigability and difficulty walking Dystrophic features with
phagocytosed fibers
No c.2235 + 1G > A
spl. + c.2235 + 1G > A spl.
XX M 42 15 4800–6600 NA NA Hyper-Ck-emia; high-arched feet Necrotizing myopathy No c.649-2A > G spl. + c.649-2A > G spl.
XXI M 35 29 2830 NA NA Hyper-Ck-emia Slight dystrophy No c.191 dupA;
p.Asn64LysfsX15 + c.1213C > T;
p.Gln405X
XXIV F 56 47 536 NA NA Autosomal dominant myopathy Myopathic changes NA c.191 dupA;
p.Asn64LysfsX15 + c.2387C > T;
p.Ser796Leu
XLII F 37 18 >1000 Normal Normal LGMD Myopathic pattern No c.1207C > T;
p.Gln403X + c.2411C > G;
p.Cys804Ser
XLIII F 23 13 >1000 Normal Normal LGMD Myopathic pattern No c.191 dupA;
p.Asn64LysfsX15 + c.1520 delT
p.Phe507SerfsX6
XLIV F 33 NA NA NA NA LGMD NA NA c.191 dupA; p.Asn64LysfsX15 + c.191
dupA; p.Asn64LysfsX15
XLV F 42 NA NA NA NA LGMD NA NA c.692G > T;
p.Gly231Val + c.2342T > C;
p.Leu781Pro
XLVI M 39 NA NA NA NA NA NA NA c.1213C > T;
p.Gln405X + c.2387C > T;
p.Ser796Leu
XLVII F NA NA NA NA NA NA NA NA c.729_730insT;
p.Asn244X + c.2387C > T;
p.Ser796Leu
Patients XV, XVI and XVII have been described elsewhere ([16]) and are not included in the table. For patients XLIV–XLVII, detailed clinical data were not available.
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ambulant, but two that occasionally use walking aids (aged 71
and 75).
When assessed, cardiac and respiratory functions were
normal with the exception of patient V, who showed a short PQ
interval, and of patient XII, who is suffering from a restrictive
respiratory insufficiency.
For 15 families, a brief summary of the phenotype was
added as Supplementary appendix. Patients XV, XVI and XVII
have been previously characterized elsewhere [13].
4. Discussion
By combining NGS and Sanger sequencing, we have carried
out the largest screening of the ANO5 gene in 786 myopathic
patients and 52 controls. In our cohort of patients, thirty-three
are homozygous or compound heterozygous for causative
mutations in ANO5. Interestingly only 18/33 are Italian
(although they are 90% of the cohort), providing a further
evidence of lower frequency of anoctaminopathies in this
country [12] where dysferlinopathies and calpainopathies still
remain the most common form of LGMD [28]. In contrast, we
have evidenced a single heterozygous variant in 3% (23/786) of
patients. Some of these may be non-pathological rare variants,
but others, such as c.191dupA, are well-known causative
mutations. When fully studied, heterozygous patients show no
hidden mutation on the second allele. Is this compatible with
the disease prevalence? Previous published papers have
evidenced the high prevalence of anoctaminopathies in
Northern Europe: in particular, a prevalence of 0.27/100,000
has been estimated in the North of England [5] and of
2/100,000 in the Finnish population [13]. However, a rarer
frequency of variants has been reported elsewhere [12].
To explain 3% of heterozygotes, we propose two hypotheses:
1 We would find a similar number of heterozygotes in any
other cohort of subjects, because the frequency of
pathological alleles is at least 10-fold higher than expected
(>0.01 instead of 0.001). This immediately indicates that
over 90% of cases with both ANO5 mutations should be
quite healthy, in the absence of a second unknown hit.
2 We have found many heterozygous subjects, because they
are true patients: this suggests that ANO5-myopathy could
be transmitted as a dominant trait, in the presence of a
second unknown hit. A point in favor of the first hypothesis
is the long list of ANO5 variants present in the Exome
Variant Server and in dbSNP: ANO5 is certainly a highly
polymorphic gene. In fact, eighty variants with a frequency
lower than 1.5% are listed in EVS (Supplementary Table S2)
for a total of 959 carriers; 20 subjects (0.3%) are
heterozygous for the well-known c.191 dupA and 159
(2.4%) show a putative damaging variant (total 3%). The
identification of a carrier of a single mutation in ANO5 gene
is not to be considered an uncommon finding and it will be
important to identify a second putative hit. Since deleterious
copy number imbalances have been estimated in 5–10% of
patients affected by neuromuscular disorders [24], copy
number variants involving noncoding regulatory regions
[29,30] could affect the ANO5 expression in some tissues.
Other explanations involve mutations in other genes
belonging to the same pathway, the effect of modifier genes,
epigenetic changes or environmental factors.
Interestingly, the phenotype–genotype analysis shows the
absence of a correlation. All the asymptomatic patients have
increased creatine kinase levels, supporting the hypothesis of
the variable expressivity of ANO5 myopathy. In our cases, the
expressivity seems to be independent of causative mutations
and also unrelated to sex and age. In particular, the lack of a
clear genotype–phenotype correlation is evident either
comparing different families or even focusing on different
patients within the same family (for example, the patient X,2,
still asymptomatic, has a younger brother presenting with
cramps and myalgia). The interfamilial variability could reflect
a specific genetic background and the putative presence of a
second hit, as postulated. On the contrary, the intra-familial
heterogeneity could be due to different external factors,
including lifestyle, sport activity and diet, which should be
further investigated.
The anoctaminopathies are also characterized by an
extremely high genetic heterogeneity [10,25]. Interestingly,
among our patients with a complete molecular diagnosis of
anoctaminopathy, c.191dupA and c.2272C > T, the most
common variation described so far, represent less than 30% of
identified mutations and they both account for only 20% of
those detected in the Italian patients. On the contrary, we have
identified 31 novel variants, confirming the genetic
heterogeneity of ANO5 and demonstrating that the simple
screening of one or two recurrent mutations cannot be
considered effective in Southern European populations
(Fig. 3).
Considering the power of next generation sequencing [23]
and the clinical and genetic variability of muscular dystrophies,
diagnostic approaches based on NGS are becoming
increasingly frequent [31]. However, for clinical and diagnostic
aims, a targeted resequencing of genes already known to be
linked to the specific pathological condition is advisable [32]
and ANO5 has to be included. Our data also demonstrate the
utility of this approach, highlighting, however, how important
the correct interpretation of the data generated by these
approaches could be. Moreover, these NGS-based strategies are
perfect to dissect the clinical variability [33], meeting, in this
way, with the next challenges of research.
In conclusion, we suggest that the terms “anoctaminopathy”
or “ANO5 myopathy” better define a heterogeneous disease
caused by mutations in the ANO5 gene, irrespective of the first
proximal (LGMD2L), distal symptoms (Miyoshi myopathy) or
characterized by other myopathic features.
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